Position
Forefront Analytics, LLC in Mereo Biopharma Group Plc
Back to the book · All holders of MREO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$2.75K$0.42 → $0.33
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 31.8K | $13.2K | — | — | — | 0.0% |
| Q1 2026 | 127.8K | $42.2K | $0.33 | −$2.75K | $31.7K | 0.0% |